I-DXd, in particular, possesses the dual capability of direct cancer cell ablation through antigen recognition and the ancillary eradication of protumor VEGFA+ neutrophils (TANs), which contributes to a more immunologically favorable TME. This evidence concerns the gene VEGFA and cancer.